Vials labelled “VACCINE Coronavirus COVID-19” and a syringe are seen in entrance of a displayed Novavax brand on this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights
Nov 28 (Reuters) – Novavax’s (NVAX.O) up to date vaccine has been granted emergency-use authorization by the World Well being Group (WHO) for lively immunization to stop COVID-19 in people aged 12 and older, the corporate mentioned on Tuesday.
The one-target vaccine is aimed on the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant within the U.S. for a lot of this 12 months however has since been overtaken by different variants because the virus evolves.
Novavax missed out on the COVID-19 vaccine windfall, which benefited rivals, on account of manufacturing points that delayed its submitting for approval throughout the peak of the pandemic.
The Maryland-based biotech’s up to date COVID shot, which was approved within the U.S. in October, makes use of a extra conventional protein-based know-how than the mRNA-based vaccines by rivals Pfizer (PFE.N) and Moderna (MRNA.O).
Reporting by Pratik Jain in Bengaluru; Enhancing by Krishna Chandra Eluri and Shweta Agarwal
Our Requirements: The Thomson Reuters Belief Rules.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.